dc.contributor.author |
Kwofie, Luyanda Laura Illicia
|
|
dc.contributor.author |
Rapoport, Bernardo Leon
|
|
dc.contributor.author |
Fickl, Heidi
|
|
dc.contributor.author |
Meyer, Pieter Willem Adriaan
|
|
dc.contributor.author |
Rheeder, Paul
|
|
dc.contributor.author |
Hlope, H.
|
|
dc.contributor.author |
Anderson, Ronald
|
|
dc.contributor.author |
Tintinger, Gregory Ronald
|
|
dc.date.accessioned |
2012-07-20T13:26:36Z |
|
dc.date.available |
2012-07-20T13:26:36Z |
|
dc.date.issued |
2012-04 |
|
dc.description.abstract |
The soluble Triggering Receptor Expressed on Myeloid cells 1 (sTREM-1) is a useful
marker of infection in patients with sepsis, but has not been adequately evaluated in
patients with chemotherapy-associated febrile neutropenia (FN). The value of
sTREM-1 in this setting has been tested in a retrospective, pilot study using stored
serum from 48 cancer patients with documented FN. On presentation, patients were
categorized according to the Talcott risk-index clinical score. Circulating soluble
sTREM-1 was measured using an ELISA procedure, while procalcitonin (PCT) or
interleukins 6 (IL-6) and 8 (IL-8), included for comparison, were measured using an
immunoluminescence-based assay and Bio-Plex suspension bead array system,
respectively. Circulating concentrations of both sTREM-1 and PCT were significantly
(P < 0.05) elevated in patients at high risk for complications or death, as predicted by
the Talcott score and were significantly lower in patients who responded to empiric
antimicrobial agents. Neither IL-6 nor IL-8 accurately predicted serious complications
in patients with FN. These observations, albeit from a pilot study, demonstrate that
sTREM-1 is indeed elevated in high-risk patients with FN and is potentially useful to
predict their clinical course, either together with, or as an alternative to PCT. |
en_US |
dc.description.uri |
http://www.springerlink.com/content/0939-5555 |
en_US |
dc.identifier.citation |
Kwofie, L, Rapoport, BL, Fickl, H, Meyer, PWA, Rheeder, P, Hlope, H, Anderson, R & Tintinger, GR 2012, 'Evaluation of circulating soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) to predict risk profile, response to antimicrobial therapy, and development of complications in patients with chemotherapy-associated febrile neutropenia : a pilot', Annals of Hematology, vol. 91, no.4, pp. 605-611, doi: 10.1007/s00277-011-1339-4. |
en_US |
dc.identifier.issn |
0939-5555 (print) |
|
dc.identifier.issn |
1432-0584 (online) |
|
dc.identifier.other |
10.1007/s00277-011-1339-4 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/19472 |
|
dc.language.iso |
en |
en_US |
dc.publisher |
Springer |
en_US |
dc.rights |
© Springer-Verlag 2011. The original publication is available at www.springerlink.com |
en_US |
dc.subject |
Febrile neutropenia (FN) |
en_US |
dc.subject |
Soluble TREM-1 |
en_US |
dc.subject |
Talcott score |
en_US |
dc.subject |
Procalcitonin |
en_US |
dc.title |
Evaluation of circulating soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) to predict risk profile, response to antimicrobial therapy, and development of complications in patients with chemotherapy-associated febrile neutropenia : a pilot |
en_US |
dc.type |
Postprint Article |
en_US |